Related Experiment Video
Updated: Sep 20, 2026

Stabilizing Hepatocellular Phenotype Using Optimized Synthetic Surfaces
Published on: September 26, 2014
Effects of poly I: poly C on rat pulmonary and hepatic cytochromes P-450 and b5
N R Mettler1, S Yano, Y Kikkawa
1Department of Pathology, New York Medical College, Valhalla 10595.
Abstract:
Interferon inducing agents such as poly I:poly C have been shown to reduce the hepatic hemoproteins cytochromes P-450 and b5 along with the associated monooxygenase activities [el Azhary and Mannering, Molec. Pharmac. 15, 698 (1979)]. In a previous study [Kikkawa et al., Lab. Invest. 50, 62 (1984)], we demonstrated that the interferon inducing agent poly I:poly C reduces pulmonary microsomal hemoprotein by 50% when administered to rats. The current investigation was conducted to characterize these changes in more detail and compare them to analogous changes in the liver. Compared to controls, cytochrome P-450 in both the lungs and livers of poly I:poly C treated rats declined by 40% at 24 hr and 55% at 48 hr (P less than 0.01). By 72 hr the decline was only 25%. In contrast, cytochrome b5 levels declined by less than 30% of control values during the first 48 hr following poly I:poly C injection (P less than 0.01) and returned to control levels by 72 hr. These changes in both cytochrome P-450 and b5 were reflected in decreases in pulmonary microsomal hemoprotein. Benzphetamine-N-demethylase activity declined by 45% in lung microsomes at 48 hr (P less than 0.01) after injection of poly I:poly C, while 7-ethoxycoumarin-O-deethylase (P less than 0.05) and 7-ethoxyresorufin-O-deethylase activities declined by approximately 41%. In the liver from these same poly I:poly C treated groups, benzphetamine-N-demethylase declined by 66% (P less than 0.05), while 7-ethoxycoumarin-O-deethylase and 7-ethoxyresorufin-O-deethylase activities declined by 60% (P less than 0.02 and P less than 0.05 respectively).
More Related Videos
10:44Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures
Published on: March 28, 2017
09:33Formation of Covalent DNA Adducts by Enzymatically Activated Carcinogens and Drugs In Vitro and Their Determination by 32P-postlabeling
Published on: March 20, 2018
Related Concept Videos
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase